Verici DX reports stronger test adoption and progress towards break-even

Verici Dx Plc

Verici DX reported continued progress in the commercial adoption of its kidney transplant diagnostic tests, with higher revenues, increased orders and a shorter sales cycle.

The company said the time required to introduce its Tutivia test at new transplant centres had fallen from around six months to three months. It also reported wider use within existing centres, with several new customers moving quickly towards repeat testing by multiple clinicians.

Verici DX had 36 ordering centres, representing around 20% of its target centres in the US. Revenue from Tutivia increased from $1.1 million to $1.8 million, supported by 825 completed tests. The company reported a gross margin of 72% and an average expected reimbursement of approximately $2,300 per test.

Orders during the first three quarters were around 52% higher year on year, with the company expecting full-year order growth of between 80% and 85%.

Verici DX is targeting cash flow break-even by the end of 2027. It said its recent £8.75 million fundraising had strengthened its financial position and provided funding to support the business towards that target. Further sales recruitment is planned to increase commercial coverage across the US.

The company is also preparing to expand its product portfolio, with a new test expected to launch by the end of 2026. This is intended to complement its existing offering and create further opportunities for revenue growth.

Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Search